HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infection
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Generation of HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infection Receiving HBV-active Antiretroviral Therapy |
- To characterize circulating and intra-hepatic anti-HBV T-cell responses longitudinally in HIV-1/HBV co-infected individuals, following effective anti-HBV therapy [ Time Frame: 48 weeks ]
- To identify novel CD4 and CD8 T cell HBV epitopes associated with HBV clearance. [ Time Frame: 48 weeks ]
- To identify emergence of cytotoxic T lymphocyte (CTL) "escape" mutants following anti-HBV therapy [ Time Frame: 48 weeks ]
- To determine the effect of HIV-1 co-infection and anti-HBV T-cell responses on clearance of free virions and HBV reservoirs using viral dynamic parameters and direct quantification of HBV hepatic reservoirs [ Time Frame: 48 weeks ]
Biospecimen Retention: Samples With DNA
| Enrollment: | 36 |
| Study Start Date: | April 2005 |
| Study Completion Date: | December 2007 |
| Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
HIV/Hepatitis coinfected patients who use at least one hepatitis activity drug or medications
|
Detailed Description:
Longitudinal study of circulating and intra-hepatic HBV-specific T-cell immunity in the setting of a randomised, controlled, international, multi-centre outpatient trial. The trial will randomise HIV/HBV co-infected individuals to different HBV-active antiretroviral therapy treatment regimens.
Study population: Patients with HIV/HBV co-infection who are naive to HIV/HBV therapy, have detectable HBV viremia and are willing to start antiretroviral therapy.
Eligibility
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- HIV positive
- hepatitis-B co-infected
- HBV/HIV therapy naive
- >18 years of age
Exclusion Criteria:
Unable to sign consent form.
Contacts and Locations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00476723
| Thailand | |
| HIV-NAT | |
| Bangkok, Thailand | |
| Principal Investigator: | Kiat Ruxrungtham, MD, MSc | HIV-NAT, The Thai Red Cross AIDS Research Centre |
More Information
Additional Information:
| Responsible Party: | Prof. Kiat Ruxrungtham, HIV-NAT |
| ClinicalTrials.gov Identifier: | NCT00476723 History of Changes |
| Other Study ID Numbers: |
HIV-NAT 032 |
| First Submitted: | November 15, 2006 |
| First Posted: | May 22, 2007 |
| Last Update Posted: | June 7, 2010 |
| Last Verified: | June 2010 |
Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
|
HIV infection Hepatitis coinfection |
Additional relevant MeSH terms:
|
Infection Hepatitis Hepatitis B Coinfection Liver Diseases Digestive System Diseases |
Hepadnaviridae Infections DNA Virus Infections Virus Diseases Hepatitis, Viral, Human Parasitic Diseases |